×
0 0 0 0 0 0 0 0
Analyst impact report

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $36.00 price target on the stock.

Intra-Cellular Therapies, Inc (ITCI)  More Company Research Source: MarketBeat
Last intra-cellular therapies, inc earnings: 8/7 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations
Impact snapshot Event time: ITCI
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ITCI alerts
from News Quantified
Opt-in for
ITCI alerts

from News Quantified
Opt-in for
ITCI alerts

from News Quantified